세계의 종양 기반 분자진단 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 제품별, 기술별, 지역별, 부문별 예측(2025-2033년)

Oncology Based Molecular Diagnostics Market Summary

The global oncology based molecular diagnostics market size was estimated at USD 3.75 billion in 2024 and is projected to reach USD 6.35 billion by 2030, growing at a CAGR of 5.5% from 2025 to 2033. This market supports the detection, prognosis, and monitoring of various cancers by identifying genetic mutations, gene expression patterns, and tumor-specific biomarkers through molecular techniques.

Growth is driven by the increasing global cancer burden, growing adoption of precision medicine, and continued innovation in diagnostic technologies such as PCR, NGS, and liquid biopsy platforms.

In addition, rising demand for early cancer detection and personalized therapeutic strategies contributes to market expansion across healthcare systems.

Oncology-based molecular diagnostics involve analyzing DNA, RNA, or proteins to detect cancer-related genetic alterations and guide clinical decisions. These tests help identify specific mutations, gene expressions, or biomarkers associated with various cancers, allowing for more accurate diagnosis, prognosis, and treatment selection. They are commonly used to detect breast, lung, colorectal, and prostate cancers.

These diagnostics play a key role in personalized medicine by helping match patients with targeted therapies and monitoring treatment response. Applications span across hospital labs, reference labs, and research institutions. With continuous improvements in technologies like PCR, next-generation sequencing (NGS), and liquid biopsy, these tests are becoming more efficient and accessible. With oncology care shifting toward individualized treatment, molecular diagnostics have become a critical component of cancer management.

Global Oncology Based Molecular Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global oncology based molecular diagnostics market report based on product, technology, type, and region:

• Type Outlook (Revenue, USD Million; 2021 - 2033)
• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Cervical Cancer
• Liver Cancer
• Lung Cancer
• Blood Cancer
• Kidney Cancer
• Others
• Product Outlook (Revenue, USD Million; 2021 - 2033)
• Instruments
• Reagents
• Others
• Technology Outlook (Revenue, USD Million; 2021 - 2033)
• PCR
• In situ hybridization
• INAAT
• Chips and microarrays
• Mass spectrometry
• Sequencing
• TMA
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

ac

Table of Contents

Chapter 1. Oncology Based Molecular Diagnostics Market: Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Type Segment
    • 1.1.1.2. Product Segment
    • 1.1.1.3. Technology segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Oncology Based Molecular Diagnostics Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Type and Product Snapshot
• 2.3. Technology Snapshot
• 2.4. Competitive Landscape Snapshot

Chapter 3. Oncology Based Molecular Diagnostics Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
  • 3.4.1. Rising Global Cancer Prevalence
  • 3.4.2. Adoption of Precision Medicine
  • 3.4.3. Advances in Molecular Testing Technologies
• 3.5. Market Restraint Analysis
  • 3.5.1. High Costs of Testing and Equipment
  • 3.5.2. Inconsistent Reimbursement and Regulatory Frameworks
  • 3.5.3. Limited Access in Low-Resource Regions
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis
• 3.8. Pipeline Analysis

Chapter 4. Oncology Based Molecular Diagnostics Market: Type Estimates & Trend Analysis

• 4.1. Oncology Based Molecular Diagnostics Market: Type Movement Analysis
• 4.2. Breast Cancer
  • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.3. Prostate Cancer
  • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.4. Colorectal Cancer
  • 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Cervical Cancer
  • 4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Liver Cancer
  • 4.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Lung Cancer
  • 4.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Blood Cancer
  • 4.8.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.9. Kidney Cancer
  • 4.9.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.10. Others
  • 4.10.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Oncology Based Molecular Diagnostics Market: Product Estimates & Trend Analysis

• 5.1. Oncology Based Molecular Diagnostics Market: Product Movement Analysis
• 5.2. Instruments
  • 5.2.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.3. Reagents
  • 5.3.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.4. Others
  • 5.4.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. Oncology Based Molecular Diagnostics Market: Technology Estimates & Trend Analysis

• 6.1. Oncology Based Molecular Diagnostics Market: Product Movement Analysis
• 6.2. PCR
  • 6.2.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.3. In situ hybridization
  • 6.3.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.4. INAAT
  • 6.4.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.5. Chips and microarrays
  • 6.5.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.6. Mass spectrometry
  • 6.6.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.7. Sequencing
  • 6.7.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.8. TMA
  • 6.8.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.9. Others
  • 6.9.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Oncology Based Molecular Diagnostics Market: Regional Business Analysis

• 7.1. Regional Market Snapshot
• 7.2. North America
  • 7.2.1. North America Oncology Based Molecular Diagnostics Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. U.S. Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.2.2.2. Key Country Dynamics
    • 7.2.2.3. Regulatory Framework
    • 7.2.2.4. Reimbursement Scenario
    • 7.2.2.5. Competitive Scenario
  • 7.2.3. Canada
    • 7.2.3.1. Canada Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.2.3.2. Key Country Dynamics
    • 7.2.3.3. Regulatory Framework
    • 7.2.3.4. Reimbursement Scenario
    • 7.2.3.5. Competitive Scenario
  • 7.2.4. Mexico
    • 7.2.4.1. Mexico Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.2.4.2. Key Country Dynamics
    • 7.2.4.3. Regulatory Framework
    • 7.2.4.4. Reimbursement Scenario
    • 7.2.4.5. Competitive Scenario
• 7.3. Europe
  • 7.3.1. Europe Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • 7.3.2. UK
    • 7.3.2.1. UK Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.3.2.2. Key Country Dynamics
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. Reimbursement Scenario
    • 7.3.2.5. Competitive Scenario
  • 7.3.3. Germany
    • 7.3.3.1. Germany Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.3.3.2. Key Country Dynamics
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Reimbursement Scenario
    • 7.3.3.5. Competitive Scenario
  • 7.3.4. Spain
    • 7.3.4.1. Spain Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.3.4.2. Key Country Dynamics
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Reimbursement Scenario
    • 7.3.4.5. Competitive Scenario
  • 7.3.5. France
    • 7.3.5.1. France Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.3.5.2. Key Country Dynamics
    • 7.3.5.3. Regulatory Framework
    • 7.3.5.4. Reimbursement Scenario
    • 7.3.5.5. Competitive Scenario
  • 7.3.6. Italy
    • 7.3.6.1. Italy Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.3.6.2. Key Country Dynamics
    • 7.3.6.3. Regulatory Framework
    • 7.3.6.4. Reimbursement Scenario
    • 7.3.6.5. Competitive Scenario
  • 7.3.7. Denmark
    • 7.3.7.1. Denmark Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.3.7.2. Key Country Dynamics
    • 7.3.7.3. Regulatory Framework
    • 7.3.7.4. Reimbursement Scenario
    • 7.3.7.5. Competitive Scenario
  • 7.3.8. Sweden
    • 7.3.8.1. Sweden Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.3.8.2. Key Country Dynamics
    • 7.3.8.3. Regulatory Framework
    • 7.3.8.4. Reimbursement Scenario
    • 7.3.8.5. Competitive Scenario
  • 7.3.9. Norway
    • 7.3.9.1. Norway Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.3.9.2. Key Country Dynamics
    • 7.3.9.3. Regulatory Framework
    • 7.3.9.4. Reimbursement Scenario
    • 7.3.9.5. Competitive Scenario
• 7.4. Asia Pacific
  • 7.4.1. Asia-Pacific Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • 7.4.2. Japan
    • 7.4.2.1. Japan Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.4.2.2. Key Country Dynamics
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Scenario
    • 7.4.2.5. Competitive Scenario
  • 7.4.3. China
    • 7.4.3.1. China Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.4.3.2. Key Country Dynamics
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Scenario
    • 7.4.3.5. Competitive Scenario
  • 7.4.4. India
    • 7.4.4.1. India Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.4.4.2. Key Country Dynamics
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Scenario
    • 7.4.4.5. Competitive Scenario
  • 7.4.5. South Korea
    • 7.4.5.1. South Korea Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.4.5.2. Key Country Dynamics
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Reimbursement Scenario
    • 7.4.5.5. Competitive Scenario
  • 7.4.6. Thailand
    • 7.4.6.1. Thailand Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.4.6.2. Key Country Dynamics
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Reimbursement Scenario
    • 7.4.6.5. Competitive Scenario
  • 7.4.7. Australia
    • 7.4.7.1. Australia Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.4.7.2. Key Country Dynamics
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Reimbursement Scenario
    • 7.4.7.5. Competitive Scenario
• 7.5. Latin America
  • 7.5.1. Latin America Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Brazil Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.5.2.2. Key Country Dynamics
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Scenario
    • 7.5.2.5. Competitive Scenario
  • 7.5.3. Argentina
    • 7.5.3.1. Argentina Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.5.3.2. Key Country Dynamics
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Scenario
    • 7.5.3.5. Competitive Scenario
• 7.6. MEA
  • 7.6.1. MEA Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • 7.6.2. South Africa
    • 7.6.2.1. South Africa Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.6.2.2. Key Country Dynamics
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Scenario
    • 7.6.2.5. Competitive Scenario
  • 7.6.3. Saudi Arabia
    • 7.6.3.1. Saudi Arabia Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.6.3.2. Key Country Dynamics
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Scenario
    • 7.6.3.5. Competitive Scenario
  • 7.6.4. UAE
    • 7.6.4.1. UAE Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.6.4.2. Key Country Dynamics
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Scenario
    • 7.6.4.5. Competitive Scenario
  • 7.6.5. Kuwait
    • 7.6.5.1. Kuwait Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.6.5.2. Key Country Dynamics
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Scenario
    • 7.6.5.5. Competitive Scenario

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
  • 8.2.1. New Type Launch
  • 8.2.2. Partnerships
  • 8.2.3. Acquisition
  • 8.2.4. Collaboration
  • 8.2.5. Funding
• 8.3. Key Company Market Share Analysis, 2024
• 8.4. Company Heat Map Analysis
• 8.5. Company Profiles
  • 8.5.1. Abbott
    • 8.5.1.1. Company Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Type Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Bayer AG
    • 8.5.2.1. Company Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Type Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. BD
    • 8.5.3.1. Company Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Type Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Cepheid
    • 8.5.4.1. Company Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Type Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Agilent Technologies, Inc.
    • 8.5.5.1. Company Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Type Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Danaher
    • 8.5.6.1. Company Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Type Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Hologic, Inc.
    • 8.5.7.1. Company Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Type Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Qiagen
    • 8.5.8.1. Company Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Type Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. F. Hoffmann-La Roche Ltd.
    • 8.5.9.1. Company Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Type Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Siemens
    • 8.5.10.1. Company Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Type Benchmarking
    • 8.5.10.4. Strategic Initiatives
  • 8.5.11. Sysmex
    • 8.5.11.1. Company Overview
    • 8.5.11.2. Financial Performance
    • 8.5.11.3. Type Benchmarking
    • 8.5.11.4. Strategic Initiatives